Skip to main content

Table 3 Genotypic distribution of 3DS1/3DL1 and the ligand among individuals in different groups

From: KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors

Allele genotype, ligand 1Low CD4 2High CD4 P 3High VL 4Low VL P 5TP 6LTNP P
(Total 83) (Total 49) (Total 84) (Total 48) (Total 83) (Total 40)
  n (%) n (%)   n (%) n (%)   n (%) n (%)  
3DS1/3DL1 20 (24.1) 19 (38.8) 0.057 23 (27.4) 16 (33.3) 0.299 20 (24.1) 15 (37.5) 0.093
3DS1/3DS1 2 (2.4) 3 (6.1) 0.266 2 (2.4) 3 (6.3) 0.253 2 (2.4) 3 (7.5) 0.194
3DL1/3DL1 61 (73.5) 27 (55.1) 0.025 59 (70.2) 29 (60.4) 0.169 61 (73.5) 22 (55.0) 0.033
3DS1/?, with 80I 2 (2.4) 9 (18.4) 0.002 7 (8.3) 4 (8.3) 0.636 2 (2.4) 9 (22.5) 0.001
3DL1/?, with 80I 11 (13.3) 15 (30.6) 0.015 13 (15.5) 13 (27.1) 0.084 11 (13.3) 14 (35.0) 0.006
3DS1/3DS1, with 80I 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)  
3DL1/3DL1, with 80I 9 (10.8) 6 (12.2) 0.508 6 (7.1) 9 (18.8) 0.043 9 (10.8) 5 (12.5) 0.501
3DS1/3DL1, with 80I 2 (2.4) 9 (18.4) 0.002 7 (8.3) 4 (8.3) 0.636 2 (2.4) 9 (22.5) 0.001
3DS1/?, no 80I 20 (24.1) 13 (26.5) 0.455 18 (21.4) 15 (31.2) 0.148 20 (24.1) 9 (22.5) 0.518
3DL1/?, no 80I 70 (84.3) 31 (63.3) 0.006 69 (82.1) 32 (66.7) 0.037 70 (84.3) 23 (57.5) 0.002
3DS1/3DS1, no 80I 2 (2.4) 3 (6.1) 0.266 2 (2.4) 3 (6.3) 0.253 2 (2.4) 3 (7.5) 0.194
3DL1/3DL1, no 80I 52 (62.7) 21 (42.9) 0.021 53 (63.1) 20 (41.7) 0.014 52 (62.7) 17 (42.5) 0.028
3DS1/3DL1, no 80I 18 (21.7) 10 (20.4) 0.523 16 (19.1) 12 (25.0) 0.277 18 (21.7) 6 (15.0) 0.267
3DS1/?, with 80 T 1 (1.2) 0 (0.0) 0.629 1 (1.2) 0 (0.0) 0.636 1 (1.2) 0 (0.0) 0.675
3DL1/?, with 80 T 7 (8.4) 1 (2.0) 0.132 5 (6.0) 3 (6.3) 0.609 7 (8.4) 1 (2.5) 0.2
3DL1/3DL1, with 80 T 6 (7.2) 1 (2.0) 0.192 4 (4.8) 3 (6.3) 0.501 6 (7.2) 1 (2.5) 0.271
3DS1/3DL1, with 80 T 1 (1.2) 0 (0.0) 0.629 1 (1.2) 0 (0.0) 0.636 1 (1.2) 0 (0.0) 0.675
3DS1/3DS1, with 80 T 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)  
3DS1/?, no 80 T 21 (25.3) 22 (44.9) 0.017 24 (28.6) 19 (39.6) 0.135 21 (25.3) 18 (45.0) 0.024
3DL1/?, no 80 T 74 (89.2) 45 (91.8) 0.431 77 (91.7) 42 (87.5) 0.314 74 (89.2) 36 (90.0) 0.579
3DL1/3DL1, no 80 T 55 (66.3) 26 (53.1) 0.094 55 (65.5) 26 (54.2) 0.136 55 (66.3) 21 (52.5) 0.102
3DS1/3DL1, no 80 T 19 (22.9) 19 (53.1) 0.041 22 (26.2) 16 (33.3) 0.25 19 (22.9) 15 (37.5) 0.071
3DS1/3DS1, no 80 T 2 (2.4) 3 (6.1) 0.266 2 (2.4) 3 (6.3) 0.253 2 (2.4) 3 (7.5) 0.194
  1. 1Low CD4, “low CD4+ T cell count” group (CD4+ T cell counts<500 cells/μl); 2High CD4, “High CD4+ T cell count” group (CD4+ T cell counts ≥ 500 cells/μl); 3High VL, “high viral load” group (HIV viral load ≥ 104 copies/ml); 4Low VL, “low viral load” group (HIV viral load<104 copies/ml); 5TP, HIV typical progressors; 6LTNP, HIV long-term nonprogressors (9 individuals were excluded for the analysis based on LTNPs or TPs, because of not meeting the criterions of LTNPs or TPs).
  2. 3DS1/L1, KIR3DS1/L1 heterozygotes; 3DS1/S1, 3DS1 homozygotes; 3DL1/L1, KIR3DL1 homozygotes.
  3. 3DS1/?, individuals with at least one copy of KIR3DS1 gene; 3DL1/?, individuals with at least one copy of KIR3DL1 gene.
  4. 80I, HLA-Bw4-80I; 80 T, HLA-Bw4-80 T.
  5. n, the number of individuals with each genotype in each group; %, the percentage of individuals with each genotype in each group
  6. Data was calculated by from Yates’s correction or Fisher’s exact test.
  7. Bold numbers indicate P value<0.05.